MEDANTA Stock Overview
Engages in the provision of healthcare services in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for MEDANTA from our risk checks.
Global Health Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,091.90 |
| 52 Week High | ₹1,513.90 |
| 52 Week Low | ₹888.95 |
| Beta | -0.31 |
| 11 Month Change | 2.26% |
| 3 Month Change | 1.14% |
| 1 Year Change | 22.14% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 162.92% |
Recent News & Updates
Recent updates
The Return Trends At Global Health (NSE:MEDANTA) Look Promising
Sep 01
With EPS Growth And More, Global Health (NSE:MEDANTA) Makes An Interesting Case
Aug 02We Think Global Health (NSE:MEDANTA) Can Manage Its Debt With Ease
Jul 15Global Health Limited's (NSE:MEDANTA) Share Price Matching Investor Opinion
May 22Global Health Limited (NSE:MEDANTA) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 22Returns On Capital Are Showing Encouraging Signs At Global Health (NSE:MEDANTA)
May 04Do Global Health's (NSE:MEDANTA) Earnings Warrant Your Attention?
Apr 12Is Global Health (NSE:MEDANTA) A Risky Investment?
Mar 22Market Participants Recognise Global Health Limited's (NSE:MEDANTA) Earnings Pushing Shares 32% Higher
Feb 13There's Been No Shortage Of Growth Recently For Global Health's (NSE:MEDANTA) Returns On Capital
Jan 18With EPS Growth And More, Global Health (NSE:MEDANTA) Makes An Interesting Case
Dec 26Global Health Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Jun 01Global Health Limited's (NSE:MEDANTA) Earnings Haven't Escaped The Attention Of Investors
Mar 30Shareholder Returns
| MEDANTA | IN Healthcare | IN Market | |
|---|---|---|---|
| 7D | 3.1% | -2.3% | -3.4% |
| 1Y | 22.1% | 36.8% | 27.0% |
Return vs Industry: MEDANTA underperformed the Indian Healthcare industry which returned 36.8% over the past year.
Return vs Market: MEDANTA underperformed the Indian Market which returned 27% over the past year.
Price Volatility
| MEDANTA volatility | |
|---|---|
| MEDANTA Average Weekly Movement | 4.1% |
| Healthcare Industry Average Movement | 5.9% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: MEDANTA has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: MEDANTA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 9,052 | Pankaj Sahni | www.medanta.org |
Global Health Limited engages in the provision of healthcare services in India. The company primarily offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, musculoskeletal disorders and orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, plastic, aesthetic and reconstructive surgery, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, ayurveda, and dietetics and nutrition. It also offers lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, blood bank and e-ICU services, and health plans, as well as operates pharmacies.
Global Health Limited Fundamentals Summary
| MEDANTA fundamental statistics | |
|---|---|
| Market cap | ₹293.22b |
| Earnings (TTM) | ₹4.88b |
| Revenue (TTM) | ₹34.63b |
60.1x
P/E Ratio8.5x
P/S RatioIs MEDANTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEDANTA income statement (TTM) | |
|---|---|
| Revenue | ₹34.63b |
| Cost of Revenue | ₹16.74b |
| Gross Profit | ₹17.89b |
| Other Expenses | ₹13.01b |
| Earnings | ₹4.88b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 18.18 |
| Gross Margin | 51.66% |
| Net Profit Margin | 14.10% |
| Debt/Equity Ratio | 9.6% |
How did MEDANTA perform over the long term?
See historical performance and comparison